Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Balsalazide

Drug Profile

Balsalazide

Alternative Names: Ao Rui Xin; Balacol; Balsalazide disodium; Balsalazine; Balzide; Basazyde; Benoquin; BX 661A; Colazal; Colazid; Colazide; Giazo; Premid

Latest Information Update: 15 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biorex Laboratories
  • Developer Pharmatel; Salix Pharmaceuticals; Takeda; Teva Pharmaceutical Industries
  • Class Anti-inflammatories; Irritable bowel syndrome therapies; Salicylates; Small molecules
  • Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ulcerative colitis
  • Discontinued Cancer; Radiation injuries

Most Recent Events

  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 21 Apr 2017 No recent reports on development identified - Registered for Ulcerative colitis in New Zealand (PO)
  • 07 Apr 2015 Launched for Ulcerative colitis in China, Philippines, Taiwan, Singapore, Thailand, Myanmar, Malaysia, Hong Kong, Indonesia, United Arab Emirates and India (PO) before April 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top